An anti-HIV-1 compound that increases steady-state expression of apoplipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G

International Journal of Molecular Medicine

Volumn 28, Issue 4, 2011, Pages 613-616

  Ejima, Tomohiko ^a   Hirota, Mayuko ^a   Mizukami, Tamio ^b   Otsuka, Masami ^a   Fujita, Mikako ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NAGAHAMA INSTITUTE OF BIO SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

Apoplipoprotein B mRNA editing enzyme catalytic polypeptide like 3G; Disulfide; Human immunodeficiency virus type 1; Proteasome; Vif

Indexed keywords

4 (DIMETHYLAMINO) 2,6 BIS[[N [2 [(2 NITROPHENYL)DITHIO]ETHYL]AMINO]METHYL]PYRIDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; PROTEASOME; UNCLASSIFIED DRUG; VIF PROTEIN;

ARTICLE; ENZYME ACTIVITY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; UBIQUITINATION;

ANTI-HIV AGENTS; BLOTTING, WESTERN; CELL LINE; CYTIDINE DEAMINASE; GENE EXPRESSION REGULATION, VIRAL; HIV-1; HUMANS; LEUPEPTINS; MOLECULAR STRUCTURE; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 79960755131     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2011.737     Document Type: Article

References (22)

1. Broder S: The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res 85: 1-18, 2010.
2. Esté JA and Cihlar T: Current status and challenges of antiretroviral research and therapy. Antiviral Res 85: 25-33, 2010.
3. Sheehy AM, Gaddis NC, Choi JD and Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650, 2002.
4. Bishop KN, Verma M, Kim EY, Wolinsky SM and Malim MH: APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4: e1000231, 2008.
5. Goila-Gaur R and Strebel K: HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5: 51, 2008.
6. Iwatani Y, Chan DSB, Liu L, Yoshii H, Shibata J, Yamamoto N, Levin JG, Gronenborn AM and Sugiura W: HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain. Proc Natl Acad Sci USA 106: 19539-19544, 2009.
7. Nathans R, Cao H, Sharova N, Ali A, Sharkey M, Stranska R, Stevenson M and Rana TM: Small molecule inhibition of HIV-1 Vif. Nat Biotechnol 26: 1187-1192, 2008.
8. Cen S, Peng ZG, Li XY, Li ZR, Ma J, Wang YM, Fan B, You XF, Wang YP, Liu F, Shao RG, Zhao LX, Yu L and Jiang JD: Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J Biol Chem 285: 16546-16552, 2010.
9. Xiao Z, Ehrlich E, Luo K, Xiong Y and Yu XF: Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J 21: 217-222, 2007. (Pubitemid 46052559)
10. Fujita M, Otsuka M and Sugiura Y: Metal-chelating inhibitors of a zinc finger protein HIV-EP1. Remarkable potentiation of inhibitory activity by introduction of SH groups. J Med Chem 39: 503-507, 1996. (Pubitemid 26041462)
11. Otsuka M, Fujita M, Sugiura Y, Yamamoto T, Inoue J, Maekawa T and Ishii S: Synthetic inhibitors of regulatory proteins involved in the signaling pathway of the replication of human immunodeficiency virus 1. Bioorg Med Chem 5: 205-215, 1997. (Pubitemid 27065364)
12. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A and Martin MA: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 59: 284-291, 1986. (Pubitemid 16013975)
13. Adachi A, Ono N, Sakai H, Ogawa K, Shibata R, Kiyomatsu T, Masuike H and Ueda S: Generation and characterization of the human immunodeficiency virus type 1 mutants. Arch Virol 117: 45-58, 1991.
14. Khamsri B, Fujita M, Kamada K, Piroozmand A, Yamashita T, Uchiyama T and Adachi A: Effects of lysine to arginine mutations in HIV-1 Vif on its expression and viral infectivity. Int J Mol Med 18: 679-683, 2006.
15. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A and Strebel K: The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol 77: 11398-11407, 2003. (Pubitemid 37271638)
16. Karczewski MK and Strebel K: Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J Virol 70: 494-507, 1996. (Pubitemid 126508818)
17. Lebkowski JS, Clancy S and Calos MP: Simian virus 40 replication in adenovirus-trandformed human cells antagonizes gene expression. Nature 317: 169-171, 1985. (Pubitemid 16243135)
18. Kimpton, J and Emerman M: Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J Virol 66: 2232-2239, 1992.
19. Willey RL, Smith DH, Lasky LA, Theodore TS, Earl PL, Moss B, Capon DJ and Martin MA: In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol 62: 139-147, 1988. (Pubitemid 18050803)
20. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
21. Fujita M, Akari H, Sakurai A, Yoshida A, Chiba T, Tanaka K, Strebel K and Adachi A: Expression of HIV-1 accessory protein Vif is controlled uniquely to be low and optimal by proteasome degradation. Microbes Infect 6: 791-798, 2004. (Pubitemid 39055540)
22. Izumi T, Takaori-Kondo A, Shirakawa K, Higashitsuji H, Itoh K, Io K, Matsui M, Iwai K, Kondoh H, Sato T, Tomonaga M, Ikeda S, Akari H, Koyanagi Y, Fujita J and Uchiyama T: MDM2 is a novel E3 ligase for HIV-1 Vif. Retrovirology 6: 1, 2009.